Rise Advisors’s CorMedix CRMD Stock Holding History

Rise Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-96	Closed	-$591	–	1571
2025 Q1	$591	Buy	+96	New	+$994	﹤0.01%	1351

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

GCM

Ghisallo Capital Management Boston, Massachusetts $5.1B AUM 39.13% 1-Year Est. Return

Rise Advisors's CRMD Position: Q2 2025 in Review

Rise Advisors sold out of CorMedix (CRMD) in Q2 2025, closing a stake of 96 shares — an estimated $591 sold.

Rise Advisors first reported a position in CRMD in Q1 2025 and held it in 1 quarter. The position peaked at $591 in Q1 2025. 172 funds tracked by Wall St. Rank hold CRMD as of Q2 2025.

Rise Advisors reported no remaining CorMedix position as of Q2 2025 after selling out during the quarter.
Rise Advisors sold 96 CorMedix shares in Q2 2025, an estimated $591.
Rise Advisors first reported a position in CorMedix in Q1 2025 and held it in 1 quarter.
Rise Advisors's CorMedix position peaked at $591 in Q1 2025.
172 funds tracked by Wall St. Rank held CorMedix as of Q2 2025.

Based on Rise Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.